Cam Gallagher is President, Interim CFO of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 633,680 shares of ZNTL, which is worth approximately $2.22 Million. The most recent transaction as insider was on May 31, 2024, when has been sold 9,597 shares (Common Stock) at a price of $11.98 per share, resulting in proceeds of $114,972. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 634K
0% 3M change
36.72% 12M change
Total Value Held $2.22 Million

Cam Gallagher Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 31 2024
SELL
Open market or private sale
$114,972 $11.98 p/Share
9,597 Reduced 1.49%
633,680 Common Stock
Feb 12 2024
SELL
Open market or private sale
$13,419 $11.44 p/Share
1,173 Reduced 0.18%
643,277 Common Stock
Feb 02 2024
SELL
Open market or private sale
$133,310 $11.54 p/Share
11,552 Reduced 1.76%
644,450 Common Stock
Feb 01 2024
BUY
Grant, award, or other acquisition
-
192,500 Added 22.69%
656,002 Common Stock
May 31 2023
SELL
Open market or private sale
$730,298 $26.3 p/Share
27,768 Reduced 5.65%
463,502 Common Stock
Feb 14 2023
SELL
Open market or private sale
$169,679 $19.96 p/Share
8,501 Reduced 1.7%
491,270 Common Stock
Feb 13 2023
SELL
Open market or private sale
$68,039 $20.42 p/Share
3,332 Reduced 0.66%
499,771 Common Stock
Feb 06 2023
SELL
Open market or private sale
$226,300 $22.63 p/Share
10,000 Reduced 1.95%
503,103 Common Stock
Feb 01 2023
BUY
Grant, award, or other acquisition
-
161,092 Added 23.89%
513,103 Common Stock
Jan 17 2023
SELL
Open market or private sale
$244,899 $24.49 p/Share
10,000 Reduced 2.76%
352,011 Common Stock
Jan 05 2023
SELL
Open market or private sale
$212,399 $21.24 p/Share
10,000 Reduced 2.69%
362,011 Common Stock
Nov 15 2022
SELL
Open market or private sale
$288,750 $23.1 p/Share
12,500 Reduced 3.25%
372,011 Common Stock
Nov 08 2022
SELL
Open market or private sale
$291,531 $23.56 p/Share
12,374 Reduced 3.12%
384,511 Common Stock
Nov 07 2022
SELL
Open market or private sale
$299,375 $23.95 p/Share
12,500 Reduced 3.05%
396,885 Common Stock
Oct 17 2022
SELL
Open market or private sale
$293,875 $23.51 p/Share
12,500 Reduced 2.96%
409,385 Common Stock
Oct 06 2022
SELL
Open market or private sale
$226,200 $22.62 p/Share
10,000 Reduced 2.32%
421,885 Common Stock
Oct 05 2022
SELL
Open market or private sale
$279,750 $22.38 p/Share
12,500 Reduced 2.81%
431,885 Common Stock
Sep 16 2022
SELL
Open market or private sale
$246,800 $24.68 p/Share
10,000 Reduced 2.2%
444,385 Common Stock
Sep 15 2022
SELL
Open market or private sale
$316,875 $25.35 p/Share
12,500 Reduced 2.68%
454,385 Common Stock
May 30 2022
BUY
Grant, award, or other acquisition
-
111,072 Added 19.22%
466,885 Common Stock
Apr 05 2022
SELL
Open market or private sale
$511,700 $51.17 p/Share
10,000 Reduced 2.73%
355,813 Common Stock
Mar 15 2022
SELL
Open market or private sale
$423,100 $42.31 p/Share
10,000 Reduced 2.66%
365,813 Common Stock
Mar 07 2022
SELL
Open market or private sale
$452,300 $45.23 p/Share
10,000 Reduced 2.59%
375,813 Common Stock
Feb 15 2022
SELL
Open market or private sale
$520,400 $52.04 p/Share
10,000 Reduced 2.53%
385,813 Common Stock
Feb 14 2022
SELL
Open market or private sale
$361,988 $50.36 p/Share
7,188 Reduced 1.78%
395,813 Common Stock

Also insider at

OCUP
Ocuphire Pharma, Inc. Healthcare
CG

Cam Gallagher

President, Interim CFO
New York, NY

Track Institutional and Insider Activities on ZNTL

Follow Zentalis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZNTL shares.

Notify only if

Insider Trading

Get notified when an Zentalis Pharmaceuticals, Inc. insider buys or sells ZNTL shares.

Notify only if

News

Receive news related to Zentalis Pharmaceuticals, Inc.

Track Activities on ZNTL